SE9100099D0 - Use of growth factor - Google Patents
Use of growth factorInfo
- Publication number
- SE9100099D0 SE9100099D0 SE9100099A SE9100099A SE9100099D0 SE 9100099 D0 SE9100099 D0 SE 9100099D0 SE 9100099 A SE9100099 A SE 9100099A SE 9100099 A SE9100099 A SE 9100099A SE 9100099 D0 SE9100099 D0 SE 9100099D0
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- prevention
- cardiac
- medicament
- improving
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 3
- 208000020446 Cardiac disease Diseases 0.000 abstract 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 102000044162 human IGF1 Human genes 0.000 abstract 2
- 208000010125 myocardial infarction Diseases 0.000 abstract 2
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 102000008934 Muscle Proteins Human genes 0.000 abstract 1
- 108010074084 Muscle Proteins Proteins 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000001243 protein synthesis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9100099A SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Use of growth factor |
IE439291A IE914392A1 (en) | 1991-01-11 | 1991-12-17 | Use of human igf-i |
ZA919977A ZA919977B (en) | 1991-01-11 | 1991-12-19 | Use of human igf-i |
NZ241108A NZ241108A (en) | 1991-01-11 | 1991-12-20 | Use of insulin-like growth factor and medicaments thereof in promoting cardiac muscle synthesis and preventing/treating heart disorders |
IL100585A IL100585A (en) | 1991-01-11 | 1992-01-05 | Use of human igf-i in the preparation of anti- cardiac disorder medicaments |
AT92903240T ATE150316T1 (de) | 1991-01-11 | 1992-01-10 | Verwendung von menschlichem igf-i |
CA002099257A CA2099257A1 (en) | 1991-01-11 | 1992-01-10 | Use of human igf-1 |
ES92903240T ES2101833T3 (es) | 1991-01-11 | 1992-01-10 | Utilizacion de igf-i humano. |
EP92903240A EP0566641B1 (en) | 1991-01-11 | 1992-01-10 | Use of human igf-i |
JP50361192A JP3566283B2 (ja) | 1991-01-11 | 1992-01-10 | 心臓疾患の予防又は治療用の医薬組成物 |
AU11669/92A AU657729B2 (en) | 1991-01-11 | 1992-01-10 | Use of human IGF-I |
US08/084,232 US5434134A (en) | 1991-01-11 | 1992-01-10 | Use of human IGF-1 to treat cardiac disorders |
PCT/SE1992/000009 WO1992011865A1 (en) | 1991-01-11 | 1992-01-10 | Use of human igf-i |
DK92903240.7T DK0566641T3 (da) | 1991-01-11 | 1992-01-10 | Anvendelse af human IGF-I. |
DE69218406T DE69218406T2 (de) | 1991-01-11 | 1992-01-10 | Verwendung von menschlichem igf-i |
EP92850004A EP0501937B1 (en) | 1991-01-11 | 1992-01-10 | Use of human IGF-I |
GR970401258T GR3023614T3 (en) | 1991-01-11 | 1997-05-30 | Use of human igf-i |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9100099A SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Use of growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9100099D0 true SE9100099D0 (sv) | 1991-01-11 |
Family
ID=20381598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9100099A SE9100099D0 (sv) | 1991-01-11 | 1991-01-11 | Use of growth factor |
Country Status (16)
Country | Link |
---|---|
US (1) | US5434134A (sv) |
EP (2) | EP0566641B1 (sv) |
JP (1) | JP3566283B2 (sv) |
AT (1) | ATE150316T1 (sv) |
AU (1) | AU657729B2 (sv) |
CA (1) | CA2099257A1 (sv) |
DE (1) | DE69218406T2 (sv) |
DK (1) | DK0566641T3 (sv) |
ES (1) | ES2101833T3 (sv) |
GR (1) | GR3023614T3 (sv) |
IE (1) | IE914392A1 (sv) |
IL (1) | IL100585A (sv) |
NZ (1) | NZ241108A (sv) |
SE (1) | SE9100099D0 (sv) |
WO (1) | WO1992011865A1 (sv) |
ZA (1) | ZA919977B (sv) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5273961A (en) * | 1992-09-22 | 1993-12-28 | Genentech, Inc. | Method of prophylaxis of acute renal failure |
US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US5661122A (en) * | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
US5610134A (en) * | 1994-04-15 | 1997-03-11 | Genentech, Inc. | Treatment of congestive heart failure |
SE9402331D0 (sv) * | 1994-07-01 | 1994-07-01 | Pharmacia Ab | New use |
US5712249A (en) * | 1994-09-08 | 1998-01-27 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
AU3760595A (en) * | 1994-10-04 | 1996-04-26 | Emory University | Methods for regulation of insulin-like growth factor i receptor |
US5741776A (en) * | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
US5565428A (en) * | 1995-05-22 | 1996-10-15 | Genentech, Inc. | Method of administration of IGF-I |
GB9605124D0 (en) | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
EP1566180A3 (en) * | 1996-08-30 | 2007-08-08 | Eli Lilly & Company | Use of GLP-1 or Analogs in Treatment of Myocardial Infarction |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6514937B1 (en) | 1997-02-25 | 2003-02-04 | Celtrix Pharmaceuticals, Inc. | Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3 |
US6015786A (en) * | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
US6025368A (en) * | 1997-02-25 | 2000-02-15 | Celtrix Pharmaceuticals, Inc. | Method for treating the symptoms of chronic stress-related disorders using IGF |
US20030069177A1 (en) | 2000-05-16 | 2003-04-10 | Genentech, Inc. | Method for treating cartilage disorders |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
US6335317B1 (en) | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
US6300271B1 (en) * | 1998-05-18 | 2001-10-09 | Phillips Petroleum Company | Compositions that can produce polymers |
CA2335391A1 (en) * | 1998-10-02 | 2000-04-13 | Kenneth Walsh | Akt compositions for enhancing survival of cells |
US7368420B1 (en) | 1998-10-02 | 2008-05-06 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Akt compositions for enhancing survival of cells |
EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
SE9901634D0 (sv) * | 1999-05-05 | 1999-05-05 | Sahltech Ab | Treatment of myocardial infarction with a substance related to the growth hormone axis |
GB0011278D0 (en) | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
US20020098167A1 (en) | 2000-07-31 | 2002-07-25 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US7547674B2 (en) * | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
US20110091428A1 (en) * | 2000-07-31 | 2011-04-21 | New York Medical College | Compositions of adult organ stem cells and uses thereof |
EP1370282A2 (en) * | 2000-10-13 | 2003-12-17 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
ES2331150T3 (es) | 2001-02-09 | 2009-12-22 | Genentech, Inc. | Metodos para identificar agonistas indirectos de igf-1. |
GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
GB0426154D0 (en) * | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
US20080103457A1 (en) * | 2005-01-11 | 2008-05-01 | Heart Failure Technologies, Inc. University Enterprise Laboratories (Uel) | Method and System for Treating Heart Failure |
EP1846021A2 (en) * | 2005-02-08 | 2007-10-24 | Japan As Represented By The President Of National Cardiovascular Center | Novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (igf-1) |
US8119123B2 (en) * | 2006-02-16 | 2012-02-21 | New York Medical College | Compositions comprising vascular and myocyte progenitor cells and methods of their use |
AU2008323719B2 (en) | 2007-11-09 | 2013-04-04 | New York Medical College | Methods for the repair and/or regeneration of damaged myocardium using variants of hepatocyte growth factor |
US20090180998A1 (en) * | 2007-11-30 | 2009-07-16 | Piero Anversa | Methods of isolating non-senescent cardiac stem cells and uses thereof |
US8512696B2 (en) | 2007-11-30 | 2013-08-20 | Autologous, Llc | Methods of isolating non-senescent cardiac stem cells and uses thereof |
EP2245140A2 (en) * | 2007-11-30 | 2010-11-03 | New York Medical College | Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
AU2008334036B2 (en) | 2007-11-30 | 2014-05-29 | New York Medical College | Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells |
CN110812369A (zh) * | 2018-08-10 | 2020-02-21 | 浙江楚沅生物科技有限公司 | 用于治疗组织坏死或改善心脏功能的药物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4272649A (en) * | 1979-04-09 | 1981-06-09 | Williams Electronics, Inc. | Processor controlled sound synthesizer |
US4738921A (en) * | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
SE8703625D0 (sv) * | 1987-09-18 | 1987-09-18 | Kabivitrum Ab | New medical use |
US4988675A (en) * | 1988-02-05 | 1991-01-29 | Ciba-Geigy Corporation | Method for preventing secondary effects |
-
1991
- 1991-01-11 SE SE9100099A patent/SE9100099D0/sv unknown
- 1991-12-17 IE IE439291A patent/IE914392A1/en not_active IP Right Cessation
- 1991-12-19 ZA ZA919977A patent/ZA919977B/xx unknown
- 1991-12-20 NZ NZ241108A patent/NZ241108A/en not_active IP Right Cessation
-
1992
- 1992-01-05 IL IL100585A patent/IL100585A/xx not_active IP Right Cessation
- 1992-01-10 DK DK92903240.7T patent/DK0566641T3/da active
- 1992-01-10 DE DE69218406T patent/DE69218406T2/de not_active Expired - Fee Related
- 1992-01-10 AT AT92903240T patent/ATE150316T1/de not_active IP Right Cessation
- 1992-01-10 EP EP92903240A patent/EP0566641B1/en not_active Expired - Lifetime
- 1992-01-10 US US08/084,232 patent/US5434134A/en not_active Expired - Fee Related
- 1992-01-10 ES ES92903240T patent/ES2101833T3/es not_active Expired - Lifetime
- 1992-01-10 AU AU11669/92A patent/AU657729B2/en not_active Ceased
- 1992-01-10 EP EP92850004A patent/EP0501937B1/en not_active Expired - Lifetime
- 1992-01-10 CA CA002099257A patent/CA2099257A1/en not_active Abandoned
- 1992-01-10 WO PCT/SE1992/000009 patent/WO1992011865A1/en active IP Right Grant
- 1992-01-10 JP JP50361192A patent/JP3566283B2/ja not_active Expired - Fee Related
-
1997
- 1997-05-30 GR GR970401258T patent/GR3023614T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69218406D1 (de) | 1997-04-24 |
GR3023614T3 (en) | 1997-08-29 |
ZA919977B (en) | 1992-09-30 |
EP0566641B1 (en) | 1997-03-19 |
US5434134A (en) | 1995-07-18 |
DE69218406T2 (de) | 1997-07-10 |
CA2099257A1 (en) | 1992-07-12 |
EP0501937B1 (en) | 1997-03-19 |
AU1166992A (en) | 1992-08-17 |
DK0566641T3 (da) | 1997-10-06 |
ES2101833T3 (es) | 1997-07-16 |
IE914392A1 (en) | 1992-07-15 |
JP3566283B2 (ja) | 2004-09-15 |
JPH06504286A (ja) | 1994-05-19 |
ATE150316T1 (de) | 1997-04-15 |
IL100585A0 (en) | 1992-09-06 |
WO1992011865A1 (en) | 1992-07-23 |
NZ241108A (en) | 1997-06-24 |
AU657729B2 (en) | 1995-03-23 |
EP0501937A1 (en) | 1992-09-02 |
IL100585A (en) | 1997-04-15 |
EP0566641A1 (en) | 1993-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9100099D0 (sv) | Use of growth factor | |
DK0754048T3 (da) | Behandling af partielt væksthormon-insentivitetssyndrom | |
FI932385A (fi) | Behandling av osteoporos genom anvaendning av somatoliberin (GRF) i en kombination med paratyreoideahormon (PTH) | |
ATE193541T1 (de) | Insulinotropes hormon | |
KR960702318A (ko) | 근육 질병 및 장애의 치료방법 | |
HUP0100928A2 (hu) | Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
MY109309A (en) | Improvements in or relating to somatostatins | |
ATE273997T1 (de) | Zyklische hexapeptid somatostatin analoga | |
DE69841279D1 (de) | Verwendung von humanem Parathyroid-hormon | |
CA2334941A1 (en) | Tnf-derived peptides for use in treating oedema | |
KR927002373A (ko) | 성장 호르몬 분비 활성을 갖는 폴리펩타이드 화합물 | |
ES2087337T3 (es) | Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos. | |
AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
DK0914148T3 (da) | Behandling af partielt væksthormonoverfølsomhedssyndrom | |
SE9201584D0 (sv) | Use of alpha-ketoglutarate | |
ATE104143T1 (de) | Kombination von phenaethanolamin und wachstumshormon. | |
IL145403A0 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients | |
IT8807016V0 (it) | Scarpa con suola zavorrabile per uso sportivo o terapeutico. | |
ES2129430T3 (es) | Analogos superactivos del factor liberador de la hormona del crecimiento. | |
ATE163652T1 (de) | Antikörper gegen das carboxy-terminale peptid des somatotropin-bindungsproteins der ratte | |
ATE350026T1 (de) | Erhaltung von körpereigenen proteinen | |
RU93058426A (ru) | Антогонист галанина, способ его получения, пептид, фармацевтический состав и способ лечения | |
ITAP930004U1 (it) | Sistema di correzione del procurvato e del recurvato per allungatori di arti |